CTLA4 and B-cell non-Hodgkin lymphoma: Using a humanized mouse model, Ma et al. [39] demonstrated a direct beneficial effect of PD-1/CTLA-4 blockade mediated by monoclonal antibodies against PD-1 or CTLA-4 alone, or in combination, on EBV-associated B cell lymphomas, thereby providing further evidence in support of this hypothesis.